Evidence map›Paper›PMID 24739416›Full record

ArticleCell cycle (Georgetown, Tex.)2014

The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways.

Israel Muro, Gloria Fang, Kacie A Gardella, Indra M Mahajan, Casey W Wright

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Israel MuroDivision of Pharmacology and Toxicology and The Center for Molecular and Cellular Toxicology; College of Pharmacy and The Institute for Cellular and Molecular Biology; The University of Texas at Austin; Austin, TX USA.
Gloria FangDivision of Pharmacology and Toxicology and The Center for Molecular and Cellular Toxicology; College of Pharmacy and The Institute for Cellular and Molecular Biology; The University of Texas at Austin; Austin, TX USA.
Kacie A GardellaDivision of Pharmacology and Toxicology and The Center for Molecular and Cellular Toxicology; College of Pharmacy and The Institute for Cellular and Molecular Biology; The University of Texas at Austin; Austin, TX USA.
Indra M MahajanDivision of Pharmacology and Toxicology and The Center for Molecular and Cellular Toxicology; College of Pharmacy and The Institute for Cellular and Molecular Biology; The University of Texas at Austin; Austin, TX USA.
Casey W WrightDivision of Pharmacology and Toxicology and The Center for Molecular and Cellular Toxicology; College of Pharmacy and The Institute for Cellular and Molecular Biology; The University of Texas at Austin; Austin, TX USA.
Institut de Biologie Moléculaire et Cellulaire · FRCellular Research (United States) · USThe University of Texas at Austin · US

Funding

Training in Molecular Toxicology/Environmental DiseaseT32ES007247 · NIEHS · UNIVERSITY OF TEXAS AUSTIN · PI RICHBURG, JOHN H · 1990 to 2014
$2.9M
NIEHS NIH HHS T32 ES007247NIEHS NIH HHS T32 ES07247
6 · The paper itself

Abstract

T cells devoid of tumor necrosis factor receptor associated factor-3 (Traf3) exhibit decreased proliferation, sensitivity to apoptosis, and an improper response to antigen challenge. We therefore hypothesized that TRAF3 is critical to the growth of malignant T cells. By suppressing TRAF3 protein in different cancerous T cells, we found that anaplastic large cell lymphoma (ALCL) cells require TRAF3 for proliferation. Since reducing TRAF3 results in aberrant activation of the noncanonical nuclear factor-κB (NF-κB) pathway, we prevented noncanonical NF-κB signaling by suppressing RelB together with TRAF3. This revealed that TRAF3 regulates proliferation independent of the noncanonical NF-κB pathway. However, suppression of NF-κB-inducing kinase (NIK) along with TRAF3 showed that high levels of NIK have a partial role in blocking cell cycle progression. Further investigation into the mechanism by which TRAF3 regulates cell division demonstrated that TRAF3 is essential for continued PI3K/AKT and JAK/STAT signaling. In addition, we found that while NIK is dispensable for controlling JAK/STAT activity, NIK is critical to regulating the PI3K/AKT pathway. Analysis of the phosphatase and tensin homolog (PTEN) showed that NIK modulates PI3K/AKT signaling by altering the localization of PTEN. Together our findings implicate TRAF3 as a positive regulator of the PI3K/AKT and JAK/STAT pathways and reveal a novel function for NIK in controlling PI3K/AKT activity. These results provide further insight into the role of TRAF3 and NIK in T cell malignancies and indicate that TRAF3 differentially governs the growth of B and T cell cancers.

Indexed as

Cell ProliferationCell Line, TumorHumansLymphoma, Large-Cell, AnaplasticSignal TransductionT-LymphocytesTNF Receptor-Associated Factor 3TNF Receptor-Associated Factor 3JAK/STATNF-κBNIKPI3K/AKTTRAF3

Identifiers

PMID24739416
PMCPMC4111755
OpenAlexW1988481857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.